Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS7264825 B2
Publication typeGrant
Application numberUS 10/600,557
Publication dateSep 4, 2007
Filing dateJun 20, 2003
Priority dateJun 21, 2002
Fee statusPaid
Also published asCA2432006A1, CA2432006C, CN1283318C, CN1480218A, DE10227914A1, DE50304336D1, EP1374854A1, EP1374854B1, US20040052841
Publication number10600557, 600557, US 7264825 B2, US 7264825B2, US-B2-7264825, US7264825 B2, US7264825B2
InventorsSebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kühn
Original AssigneeHerseus Kulzer Gmbh
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pharmaceutical preparation with retarding active ingredient release, method for its production and its use
US 7264825 B2
Abstract
The invention describes pharmaceutical preparations with retarding active ingredient release, which consist of mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant. The pharmaceutical preparations are used as permanent or as temporary implants in the form of tablets, molded bodies, fibers and granules.
Images(4)
Previous page
Next page
Claims(10)
1. A dry pharmaceutical preparation comprising a dry mixture of powdery teicoplanin and at least one powdery, water soluble salt form of at least one of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant.
2. The dry pharmaceutical preparation pursuant to claim 1, which contains calcium carbonate, calcium sulfate dihydrate, tricalcium phosphate and/or hydroxylapatite as the inorganic adjuvant.
3. The dry pharmaceutical preparation pursuant to claim 1, which contains polyesters of at least one of lactic acid, glycolic acid, 5-hydroxy valerie acid, 6-hydroxy caproic acid and co-polymers thereof as organic adjuvants.
4. The dry pharmaceutical preparation pursuant to claim 1, which is in the form of one of tablets, molded bodies, fibers and granules.
5. The dry pharmaceutical preparation pursuant to claim 1, comprising a combination of polymerizable methacrylic acid esters and mixtures consisting of powdery teicoplanin and at least one powdery, water soluble salt form of at least one of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin formed and polymerized into a molded body.
6. The dry pharmaceutical preparation pursuant to claim 1, wherein the mixture is part of a resorbable and/or of non-resorbable coating, which has been applied to non-metallic and metallic implants.
7. The dry pharmaceutical preparation pursuant to claim 1, wherein before being cured inorganic calcium phosphate bone cements and plaster mixtures are admixed to mixtures consisting of powdery teicoplanin and at least one powdery, water soluble salt form of at least one of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and/or ciprofloxacin.
8. A permanent or temporary implant comprising a dry pharmaceutical preparation pursuant to claim 1 in the form of one of tablets, molded bodies, fibers and granules.
9. A method of treating a bacterial infection in a patient in need thereof comprising administering to said patient a pharmaceutical preparation pursuant to claim 1.
10. A method of preparing the dry pharmaceutical preparation according to claim 1, said method comprising dry mixing powdery teicoplanin and at least one powdery, water soluble salt form of at least one of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant.
Description

The present invention relates to a pharmaceutical preparation with retarding active ingredient release as resorbable and also as non-resorbable implants in human and veterinary medicine for the treatment of severe, local bacterial infections in hard and soft tissues. The pharmaceutical preparation in particular shall be used in the therapy of bacterial infections, which due to resistance appearances are no longer accessible with a simple local antibiotic treatment with only one antibiotic. The invention furthermore relates to a method for the production and the use of the preparation.

The treatment of local microbial infections of hard and soft tissues in human and veterinary medicine requires high local concentrations of antibiotics in the infected tissue area. It has been known for quite some time that the systemic application of antibiotics is associated with a series of problems. The systemic application often requires the use of very high doses of antibiotics in order to achieve anti-microbially effective antibiotics concentrations in the infected tissue. Thus, particularly with the use of aminoglycoside antibiotics, severe damage to the organism can occur due to their nephro-and oto-toxicity. It has therefore been suggested to use antibiotics in topical release systems, or transfer them into suitable controlled-release preparations. It is furthermore useful if the topical release systems exhibit a high level of active ingredient release during the first few hours and subsequently over the course of several days release a continuous low level of active ingredient quantities to largely achieve that the bacterial pathogens are killed.

Teicoplanin is a glycopeptide antibiotic, which is effective towards Gram-positive bacterial germs. It inhibits mureic synthesis and thus cross-linkage of the bacterial cell walls. Teicoplanin is especially beneficial in that it has a considerably higher shelf life than β-lactam antibiotics and that it can be used for patients that are allergic to penicillin. Aminoglycoside antibiotics, such as gentamicin and kanamycin, and also clindamycin impair bacterial protein synthesis and thus have a bactericidal effect with many Gram-positive bacteria, anaerobic bacteria and in part also with Gram-negative bacteria. Fluor-quinolone antibiotics, such as ciprofloxacin and moxifloxacin, represent broad-band antibiotics and act as topoisomerase inhibitors and as gyrase inhibitors against a variety of Gram-positive bacteria. In the treatment of problematic germs it is therefore useful to combine two antibiotics, which have different attack methods in the bacterial metabolism, with each other. This increases the probability of an effective treatment of this problematic germs.

EP 0 611 571 reveals a topical medication with delayed release in the form of a dry product or a suspension, in an inert liquid carrier, containing the combination of teicoplanin and another medication with alkaline character as the hardly water soluble product. As the alkalene medication the aminoglycosides gentamicin, netilmicin and tobramycin are mentioned. In this disclosure document, hardly soluble reaction products made of teicoplanin with gentamicin, teicoplanin with netilmicin as well as teicoplanin with tobramycin are claimed, which are used as topical medications in the form of dry products or a suspension.

Until now no publications are known which describe pharmaceutical preparations that consist of mixtures of powdery teicoplanin and powdery water soluble salts of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and suitable inorganic and/or organic adjuvants and that exhibit a delayed active ingredient release effect in an aqueous environment.

The invention is based on the task of developing a pharmaceutical preparation that contains teicoplanin and other antibiotics and that releases the antibiotics over a period of several days in a delayed effect in an aqueous environment, such as under physiological conditions.

The task is resolved pursuant to the present invention through the features of the broad and preferred descriptions hereinbelow.

The invention is based on the surprising finding that mixtures consisting of powdery teicoplanin and at least one powdery, water soluble salt of at least one of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin exhibit a delayed active ingredient release in an aqueous environment in the presence of suitable inorganic adjuvants and/or organic adjuvants. It is surprising that contrary to EP 0 611 571, where slightly water soluble adducts of the teicoplanin and other antibiotics are used as medications, in the invented pharmaceutical preparation no synthesis of hardly soluble teicoplanin antibiotics adducts is required and that nevertheless a delayed release of antibiotics of the invented pharmaceutical preparation in an aqueous environment is found. The pharmaceutical preparation can be produced in the conventional manner for pharmaceutics, as in EP 0 611 571. The pharmaceutical preparation is furthermore suited for several combinations made of teicoplanin and other antibiotics. The pharmaceutical preparation can be accomplished with various adjuvants in tablet form.

Pursuant to the invention it is preferred that calcium carbonate, calcium sulfate dihydrate, tri-calcium phosphate and hydroxylapatite are used as the inorganic adjuvants.

It is furthermore beneficial pursuant to the invention that polyesters of the lactic acid, glycolic acid, 5-hydroxy valeric acid and 6-hydroxy caproic acid are used as organic adjuvants as well as their co-polymers are organic adjuvants.

It is preferred that the mixtures are formed through pressing, extrusion, spinning and granulation into tablets, molded bodies, fibers and granules.

It is furthermore beneficial that a combination of polymerizable methacrylic acid esters and mixtures consisting of powdery teicoplanin and powdery, water soluble salts of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin is polymerized into a molded body. Pursuant to the invention these are in particular balls or cylindrical bodies consisting of polymeric methacrylic acid esters, which contain the invented mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin, and can be used as implantable active ingredient carriers, similar to the Septopal® chains, for local infection treatment purposes. It is also in accordance with the invention that the invented mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin can be contained in bone cements. The term molded bodies should also be interpreted as cured bone cements.

Pursuant to the invention the mixtures consisting of powdery teicoplanin and powdery, water soluble salts of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin can be admixed to inorganic calcium phosphate bone cements before said cements are cured. It is also pursuant to the invention that the mixtures are used in self-curing calcium sulfate mixtures for filling in bone defects.

It is useful that the mixtures are part of resorbable and non-resorbable coatings, which are applied to non-metallic and metallic implants.

Pursuant to the invention the pharmaceutical preparation shall be used in the form of tablets, molded bodies, fibers and granules as permanent implants and as temporary implants.

The invention shall be explained in the following through the examples 1 through 3 in more detail, however without limiting the invention.

EXAMPLE 1

A mixture of 500.0 mg calcium sulfate dihydrate (Fluka), 125.0 mg poly-L-lactide (M-10,000 g/mol), 18.7 mg gentamicin sulfate (AK 628) and 18.7 mg teicoplanin is ground together. 200 mg of this mixture, respectively, are pressed in a press at a pressure of 5 tons within a period of two minutes to disk-shaped molded bodies with a diameter of 13 mm.

EXAMPLE 2

A mixture of 500.0 mg calcium sulfate dihydrate (Fluka), 125.0 mg poly-L-lactide (M-10,000 g/mol), 18.7 mg clindamycin hydrochloride and 18.7 mg teicoplanin is ground together. 200 mg of this mixture, respectively, are pressed in a press at a pressure of 5 tons within a period of two minutes to disk-shaped molded bodies with a diameter of 13 mm.

EXAMPLE 3

A mixture of 1,000.0 mg calcium sulfate dihydrate (Fluka), 250.0 mg poly-L-lactide (M-10,000 g/mol), 18.7 mg kanamycin sulfate (Fluka) and 18.7 mg teicoplanin is ground together. 200 mg of this mixture, respectively, are pressed in a press at a pressure of 5 tons within a period of two minutes to disk-shaped molded bodies with a diameter of 13 mm.

Antibiotics Release Experiments

The molded bodies produced in the examples 1-3 were introduced into Sërensen buffer with pH 7.4 and stored in it at 37° C. over a period of 12 days. Sampling took place on a daily basis, wherein the release medium was replaced. The release of antibiotics from the molded bodies was traced with an agar diffusion test while employing bacillus subtilis ATCC 6633 as the test germ. The inhibiting areola diameter was determined with the aid of a scanner and evaluated with special evaluation software. The results are depicted in the table.

TABLE
Results of the microbial agar diffusion test used to determine the release of
antibiotics from the molded bodies from examples 1-3 in dependency upon the
storage time of the sample bodies in the Sörensen buffer at 37° C.
Example 1 Example 2 Example 3
Inhibiting Inhibiting
Areola Areola Inhibiting
Diameter Diameter Areola
Time [d] Dilution [mm] Dilution [mm] Dilution Diameter [mm]
1  1:100 22.40  1:100 20.00  1:70 20.35
2  1:15 20.85 1:30 20.80 1:5 21.15
3 1:3 20.28 1:14 19.80 Undiluted 21.45
6 Undiluted 18.25 Undiluted 21.55 Undiluted 14.20
9 Undiluted 15.63 Undiluted 18.35 Undiluted Not determined
12 Undiluted 17.70 undiluted 21.30 Undiluted 15.25

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4283799 *Sep 10, 1979Aug 18, 1981Massachusetts Institute Of TechnologyPre-coated body implant
US4588583 *Oct 25, 1983May 13, 1986Beiersdorf AktiengesellschaftSurgical material
US5797873 *Nov 10, 1997Aug 25, 1998Merck Patent Gesellschaft Mit Beschrankter HaftungProcess for the preparation of bone cements comprising active compounds
US20020004071Jul 5, 2001Jan 10, 2002Cherukuri Subraman RaoRapid-melt semi-solid compositions, methods of making same and methods of using same
EP0611571A1Feb 16, 1994Aug 24, 1994Melzer, Wolfgang Dr.Teicoplanin containing topical compositions with delayed release of the active agent
WO2002009783A1Aug 1, 2000Feb 7, 2002Joerg BauerModular implant system containing active substances and method for the production thereof
Non-Patent Citations
Reference
1 *Salaria, M. Indian Pediatrics Apr. 2001; 38:372-375, downloaded from the world wide web at www.indianpediatrics.net/april2001/april-372-375.htm on Jun. 14, 2006.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8252851 *Sep 26, 2007Aug 28, 2012Young Anne MargaretFormulations and composites with reactive fillers
Classifications
U.S. Classification424/489, 424/400
International ClassificationA61P31/04, A61K9/20, A61K31/7052, A61K31/496, A61K47/02, A61K38/14, A61K9/00, A61K9/22, A61K47/04, A61K31/7056, A61K45/06, A61K47/14, A61K31/4709, A61M37/00, A61K31/7036, A61K9/14, A61K47/34
Cooperative ClassificationA61K9/0024, A61K9/2009, A61K9/204, A61K45/06, A61K38/14
European ClassificationA61K38/14, A61K9/00M5D, A61K9/20H6D4, A61K45/06, A61K9/20H2
Legal Events
DateCodeEventDescription
Feb 26, 2015FPAYFee payment
Year of fee payment: 8
Jan 7, 2014ASAssignment
Owner name: HERAEUS MEDICAL GMBH, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HERAEUS KULZER GMBH;REEL/FRAME:031905/0674
Effective date: 20131204
Feb 25, 2011FPAYFee payment
Year of fee payment: 4
Oct 27, 2003ASAssignment
Owner name: HERAEUS KULZER GMBH & CO. KG, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VOGT, SEBASTIAN DR.;SCHNABELRAUCH, MATTHIAS DR.;KUHN, KLAUS-DIETER DR.;REEL/FRAME:014077/0517;SIGNING DATES FROM 20030924 TO 20031007